Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, People's Republic of China.
IUBMB Life. 2018 Mar;70(3):183-191. doi: 10.1002/iub.1722. Epub 2018 Feb 2.
Platinum-based chemotherapy agents are widely used in the treatment of various solid malignancies. However, their efficacy is limited by drug resistance. Recent studies suggest that copper efflux transporters, which are encoded by ATP7A and ATP7B, play an important role in platinum drug resistance. Over-expressions of ATP7A and ATP7B are observed in multiple cancers. Moreover, their expressions are associated with cancer prognosis and treatment outcomes of platinum-based chemotherapy. In our review, we highlight the roles of ATP7A/7B in platinum drug resistance and cancer progression. We also discuss the possible mechanisms of platinum drug resistance mediated by ATP7A/7B and provide novel strategies for overcoming resistance. This review may be helpful for understanding the roles of ATP7A and ATP7B in platinum drug resistance. © 2018 IUBMB Life, 70(3):183-191, 2018.
基于铂的化疗药物被广泛用于治疗各种实体恶性肿瘤。然而，其疗效受到耐药性的限制。最近的研究表明，铜外排转运蛋白，由 ATP7A 和 ATP7B 编码，在铂类药物耐药性中发挥重要作用。在多种癌症中观察到 ATP7A 和 ATP7B 的过度表达。此外，它们的表达与癌症的预后和铂类化疗的治疗结果相关。在我们的综述中，我们强调了 ATP7A/7B 在铂类药物耐药性和癌症进展中的作用。我们还讨论了由 ATP7A/7B 介导的铂类药物耐药的可能机制，并提供了克服耐药性的新策略。本综述可能有助于了解 ATP7A 和 ATP7B 在铂类药物耐药性中的作用。©2018IUBMBLife，70（3）：183-191，2018。
